<DOC>
	<DOCNO>NCT01367262</DOCNO>
	<brief_summary>An open-label study conduct determine metabolism physiological disposition radiolabeled LY2886721 single dose healthy male subject .</brief_summary>
	<brief_title>Disposition 14C-LY2886721 Following Oral Administration Healthy Human Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male determine medical history physical examination Males sterile ( include vasectomy ) subject sterile sexually active , agree use Checkin 3 month exit/discharge , 1 follow approve method contraception : male condom spermicide , sterile sexual partner , use female sexual partner intrauterine device spermicide , female condom spermicide , contraceptive sponge spermicide , diaphragm spermicide , cervical cap spermicide , oral , implantable , transdermal , intravaginal , injectable contraceptive Have body mass index 19 30 kg/m2 Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Have venous access sufficient allow blood sample Have normal blood pressure heart rate ( sit ) Experience minimum least 1 bowel movement per day Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly institutional review board ( IRB ) govern site Are currently enrol , complete , discontinue within last 30 day , clinical trial involve investigational product investigational product use study ; concurrently enrol type medical research judge scientifically medically compatible study Have know allergy LY2886721 , related compound , component formulation Are person previously receive investigational product study , complete withdrawn study study investigate LY2886721 Have Bazett 's correct QT ( QTcB ) interval value &gt; 450 msec ( male ) abnormality 12lead Electrocardiograph ( ECG ) increase risk associate participate study Have abnormal blood pressure Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus ( HIV ) infection and/or positive HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Intend use prescription medication , overthecounter medication , herbal preparation contain St. John 's Wort , kava , garlic , ginger , ginko biloba , guarna within 14 day prior admission Eating grapefruit grapefruitcontaining food , drink grapefruitcontaining juice within 7 day prior dose time study Have use tobacco nicotinecontaining product ( include , limited , cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine lozenge , nicotine gum ) within 6 month prior dose Have donate blood 500 mL within last month Have average weekly alcohol intake exceed 21 unit per week ( male age 65 ) , unwilling stop alcohol consumption 48 hour prior checkin end study ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Show evidence significant active neuropsychiatric disease , particular evidence significant medical psychiatric illness within past 12 month . Have condition would preclude participation study Have history presence epilepsy , history seizure , know brain abnormality , history significant brain injury Have participate 14Cstudy within last 6 month prior Checkin study . The total exposure study previous study must within Code Federal Regulations ( CFR ) recommend level consider safe ( per 21 CFR 361.1 ) , less 5,000 mrem/year whole body annual exposure Exposure significant radiation within 12 month prior dose ( example , serial Xray compute tomography scan , barium meal , current employment job require radiation exposure monitoring ) Have history clinically significant adverse drug reaction `` drug allergy '' 3 type systemically administer medication ( penicillin cephalosporin may consider 1 type medication purpose ) Have history , current , significant ophthalmological disease Have evidence active renal disease ( example , diabetic renal disease , polycystic kidney disease ) creatinine clearance &lt; 80 mL/min ( calculate CockcroftGault equation ) : Men : ( 140 age ) x ( weight kg ) 72 x ( serum creatinine mg/dL )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Absorption</keyword>
	<keyword>Distribution</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Excretion</keyword>
</DOC>